The $20B Question: Why Behavior Still Feels Elusive 

US Pharma spends approximately $20 billion each year marketing to Healthcare Professionals (HCPs). Yet a fundamental challenge persists: truly understanding what drives consumer behavior. Despite advances in analytics, a disconnect remains between messaging and outcomes. This gap is often attributed to data limitations, but it stems from a deeper issue in how behavior is modelled. 

The Limits of Traditional Persona Frameworks 

Most persona approaches today rely on static segmentation and historical data. While effective for categorization, they fail to explain behavioral variability. They cannot fully address why similar HCPs respond differently, how decision-making evolves, or what factors truly drive action. The issue is not the lack of data, but the absence of modelling frameworks that capture complexity, context, and change. 

From Description to Behavioral Modelling 

There is a clear opportunity to reposition personas as dynamic, behavior-driven models. By grounding personas in real-life signals that capture lived experiences, constraints, and decision drivers, personas can evolve beyond descriptive tools. Structuring personas across populations, sub-populations, and behavioral archetypes enables a more granular, longitudinal understanding of behavior throughout the drug lifecycle. This shift transforms personas into a modelling layer that supports prediction, simulation, and optimization. 

Synthetic Data as a Modelling Optimization Layer 

Synthetic datasets are gaining attention in the industry, often for simulating stakeholder interactions or generating AI-driven personas. At Talking Medicines, our approach is different. Instead of focusing on simulated conversations or standalone synthetic personas, we leverage synthetic data to enhance the modelling of personas. Synthetic data serves as a critical input, enabling expanded coverage beyond observable datasets, exploration of edge cases, and controlled testing of behavioral scenarios. This approach strengthens persona models by improving robustness, reducing bias, and increasing consistency- especially where data is limited or uneven. 

For us, synthetic data is not an output- it is a critical input that drives more accurate and robust modelling. 

Bridging Messaging and Behavior 

When personas are treated as dynamic models rather than static segments, they become a vital bridge between messaging and behavior. They clarify the connection between what is communicated, how it is perceived, and how decisions are made in practice. This approach fosters a more actionable and testable understanding of HCP behavior- one that continuously evolves as new data and signals emerge.  

Conclusion 

Closing the gap between insight and impact in Pharma will not be achieved through more data alone. It requires a fundamental shift toward better modeling; models that reflect real-life complexity, that can be stress-tested, and continuously refined. In an industry investing $20 billion annually in HCP engagement, the persistent challenge is not a shortage of data, but the need for strategic modeling that truly captures the drivers of behavior. 

Reframing personas as dynamic, behavior-driven models – supported by synthetic data as an optimization layer – represents a meaningful step in this direction. This approach enables deeper, more actionable insights by expanding coverage, exploring edge cases, and improving robustness where real-life data is limited. Ultimately, the goal is not just to understand who we are targeting, but to understand what will actually change behavior, aligning messaging with measurable, outcomes and delivering lasting impact across the healthcare ecosystem. 

References

• Why Pharma is Going Direct to Customers 
• From Product to Customer Experience the New Way to Launch in Pharma 
• Applications of Machine Learning in Drug Discovery and Development  
• Health Data Governance for the Digital Age – IMPLEMENTING THE OECD RECOMMENDATION ON HEALTH DATA GOVERNANCE 
• The Ultimate CIO Toolkit for Navigating 2026 Successfully
• U.S. health care industry spends $30 billion a year on marketing